Emergence Therapeutics is a European biopharmaceutical company developing novel antibody drug conjugate (ADC) immuno-therapeutics to treat high need cancers. The lead program features innovative antibody design as well as state of the art linker and payload technology to target Nectin-4 – an important and validated target for a broad range of cancers.
Year of investment
2021
Sector
Drug development
Location
Duisburg, Germany
Website
http://emergencetx.com/
Year of investment
2021
Sector
Drug development
Location
Duisburg, Germany
Website
http://emergencetx.com/
Location: Germany, North Rhine-Westphalia, Duisburg
Total raised: $98.47M
Investors 5
| Date | Name | Website |
| - | Kurma Part... | kurmapartn... |
| 28.12.2021 | Hadean Ven... | hadeanvent... |
| - | Gründerfon... | gruenderfo... |
| 17.07.2021 | High-Tech ... | htgf.de |
| - | Pontifax V... | pontifax.c... |
Funding Rounds 1
| Date | Series | Amount | Investors |
| 14.12.2021 | Series A | $98.47M | - |
Mentions in press and media 9
| Date | Title | Description |
| 21.12.2023 | Hadean Ventures announces oversubscribed final close of Hadean Capital II | Hadean Ventures announces oversubscribed final close of Hadean Capital II – a fund dedicated to investments in life science start-ups across Europe Oslo, 21 December 2023. Hadean Ventures announced today the final close of Hadean Capital I... |
| 09.10.2023 | Who are the Pioneers of Germany’s Innovative Fitness Startup Scene? | There’s no denying that health and wellness has become an integral part of our daily lives. Thanks to tech advancement, fitness startups are taking center stage, offering innovative solutions that push the boundaries of how we approach heal... |
| 19.09.2023 | Who are Nordrhein-Westfalen’s Top Health Care Innovators Changing the Industry? | Welcome to our revelatory piece dedicated to shining a light on a collective of astounding Health Care startups hailing from the quintessential region of Nordrhein-Westfalen, Germany. A sector that continues to grow in profound magnitude, t... |
| 20.06.2023 | Biotech Breakthroughs: Unraveling Germany’s 15 Emerging Biotechnology Startups | Emergence Therapeutics led by Jack Elands, is a promising biopharmaceutical company dedicated to advancing novel ADC immunotherapies to address cancers with high unmet needs. Table of Contents show 1 FaCellitate – Supporting Drug Discover... |
| 14.12.2021 | Emergence Therapeutics Secures €87M in Series A Financing | Emergence Therapeutics AG, a Duisburg, Germany-based biopharmaceutical company developing novel antibody drug conjugates (ADC) for the treatment of cancers, closed an €87m series A financing round. The round was led by Pontifax Venture Capi... |
| 10.12.2021 | Emergence Therapeutics raises €87 million Series A financing to advance Nectin-4 ADC | Duisburg, Germany, 7 December 2021. Emergence Therapeutics AG, a biopharmaceutical company developing novel antibody drug conjugates (ADC) for the treatment of cancers with high unmet needs, today announces that it has closed an €87 million... |
| 07.12.2021 | Emergence Therapeutics raises €87 million Series A financing to advance Nectin-4 ADC | Emergence Therapeutics raises €87 million Series A financing to advance Nectin-4 ADC Series A round led by Pontifax and includes new and existing investors Lead product is a next-generation Nectin-4 ADC designed to increase efficacy and min... |
| - | Emergence Therapeutics Announces a Bumped-up Follow-on Seed Round Financing | Emergence Therapeutics AG, a European biopharmaceutical company developing novel antibody drug conjugate (ADC) immuno-therapeutics to treat high need cancers, announces that is has closed a Bumped-up Follow-on Seed Round Financing from a sy... |
| - | Emergence Therapeutics raises €87 million Series A financing to advance Nectin-4 ADC | December 7, 2021 |